H
Hassan Dianat-Moghadam
Researcher at Tabriz University of Medical Sciences
Publications - 34
Citations - 571
Hassan Dianat-Moghadam is an academic researcher from Tabriz University of Medical Sciences. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 8, co-authored 16 publications receiving 229 citations. Previous affiliations of Hassan Dianat-Moghadam include University of Tabriz & Baqiyatallah University of Medical Sciences.
Papers
More filters
Journal ArticleDOI
Cancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems.
Hassan Dianat-Moghadam,Maryam Heidarifard,Rana Jahanban-Esfahlan,Yunes Panahi,Hamed Hamishehkar,Farhad Pouremamali,Reza Rahbarghazi,Mohammad Nouri +7 more
TL;DR: In this article, a small subpopulation of cancer cells known as cancer stem cells (CSCs) are shown to be responsible for deriving clonal heterogeneity/diversity in tumors, which render them resistant to conventional treatment regimes.
Journal ArticleDOI
miRNA-based strategy for modulation of influenza A virus infection.
Mohsen Keshavarz,Hassan Dianat-Moghadam,Vahideh Hamidi Sofiani,Mohammad Karimzadeh,Mohsen Zargar,Mohsen Moghoofei,Hamed Biglari,Saied Ghorbani,Javid Sadri Nahand,Hamed Mirzaei +9 more
TL;DR: Various roles of miRNAs and exosomes in influenza A pathogenesis are summarized and therapeutic applications of miRNA as well as other effective players have been highlighted.
Journal ArticleDOI
The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance.
Hassan Dianat-Moghadam,Mehdi Azizi,Zahra Eslami-S,Luis Enrique Cortés-Hernández,Maryam Heidarifard,Mohammad Nouri,Catherine Alix-Panabières +6 more
TL;DR: A comprehensive understanding of CTCs will provide more opportunities to determine their clinical utility and provide much-needed insights into this dynamic field of translational cancer research.
Journal ArticleDOI
Natural killer cell-based immunotherapy: From transplantation toward targeting cancer stem cells.
TL;DR: An overview of the emerging knowledge of the characteristics, diversities, and mechanism‐driven immune surveillance of human NK cells and advances in NK cell–based immunotherapies is presented.
Journal ArticleDOI
TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies.
Hassan Dianat-Moghadam,Maryam Heidarifard,Amir Mahari,Mehdi Shahgolzari,Mohsen Keshavarz,Mohammad Nouri,Zohreh Amoozgar +6 more
TL;DR: The complex biology of TRAIL signaling, including TRAILs cross-talk with other signaling pathways and immune cells, is summarized and strategies with the potential to overcome the challenges that cannot be addressed via nanotechnology alone are specified.